Literature DB >> 28965239

Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center.

Priscila Dentini1, Fernando Augusto Lima Marson2,3, Luciana Cardoso Bonadia4, Carmen Sílvia Bertuzzo4, Antônio Fernando Ribeiro1, Carlos Emílio Levy5, José Dirceu Ribeiro1.   

Abstract

The Burkholderia cepacia complex (BCC) can cause a severe decline in lung function in cystic fibrosis (CF). Our objective was to determine the BCC prevalence and to evaluate its clinical impact on CF. Clinical and laboratory variables were determined for CF patients with BCC (Group-A = 50 patients) and without BCC (Group-B = 134 patients). The microorganisms were identified by biochemical tests, the Vitek2®Compact test, recA-PCR and recA-nested-PCR with species-specific primers and DNA sequencing. The patients were evaluated by the Shwachman-Kulczycki score (SKCS), Bhalla score (BS), spirometry and body mass index (BMI). The BCC prevalence was 22.5%. The most common species were Burkholderia multivorans (30%), Burkholderia cepacia (24%), Burkholderia cenocepacia IIIA (10%), B. cenocepacia IIIB (2%) and Burkholderia vietnamiensis (2%). There was difference between the groups in nutritional status (p = 0.02) and general activity (p = 0.026). There was difference in total BS points (p = 0.04) and the following parameters: bronchiectasis severity (p = 0.007), peribronchial thickening (p = 0.013), bronchiectasis extent (p = 0.01) and general aspects of the affected bronchial zone (p = 0.02). The respiratory disorder classifications were as follows: obstructive-4.8% (Group-A) and 23.8% (Group-B); restrictive-9.5% (Group-A and Group-B); obstructive + restrictive-19% (Group-A) and 1.6% (Group-B); and obstructive + restrictive with a decreased forced expiratory flow-47.6% (Group-A) and 30.2% (Group-B) (p = 0.02). Nutritional status was a minor contributing factor to weight, height and BMI in the Group-A (p = 0.02). The BCC prevalence, particularly the prevalence of B. multivorans, was higher in this study. The SKCS, BS, spirometry and nutritional status results showed that BCC has a negative impact on clinical status. Phenotypic methods are useful for the identification of presumptive BCC. The Vitek2®Compact test showed accuracy in BCC identification. PCR, nested-PCR, and recA sequencing showed specificity in BCC species identification.

Entities:  

Keywords:  Burkholderia cepacia complex; Cystic fibrosis; Molecular diagnostic; Prevalence

Mesh:

Year:  2017        PMID: 28965239     DOI: 10.1007/s00430-017-0521-2

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  60 in total

1.  A 5 YEAR CLINICAL EVALUATION OF A THERAPEUTIC PROGRAM FOR PATIENTS WITH CYSTIC FIBROSIS.

Authors:  C F DOERSHUK; L W MATTHEWS; A S TUCKER; H NUDLEMAN; G EDDY; M WISE; S SPECTOR
Journal:  J Pediatr       Date:  1964-11       Impact factor: 4.406

Review 2.  Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials.

Authors:  Sara Hernando-Amado; Paula Blanco; Manuel Alcalde-Rico; Fernando Corona; Jose A Reales-Calderón; María B Sánchez; José L Martínez
Journal:  Drug Resist Updat       Date:  2016-06-30       Impact factor: 18.500

3.  Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status.

Authors:  A Agodi; E Mahenthiralingam; M Barchitta; V Gianninò; A Sciacca; S Stefani
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

4.  Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

Authors:  P Vandamme; B Holmes; M Vancanneyt; T Coenye; B Hoste; R Coopman; H Revets; S Lauwers; M Gillis; K Kersters; J R Govan
Journal:  Int J Syst Bacteriol       Date:  1997-10

5.  Report - Prevalence of hospital acquired Burkholderia cepacia infection and its antimicrobial susceptibility in a Chinese hospital.

Authors:  Jinju Duan; Jianbang Kang; Ting Han; Yuqin Ma; Qian Guo; Yan Song; Qiang Zhao; Yan Yang; Ruiqin Zhang
Journal:  Pak J Pharm Sci       Date:  2017-03       Impact factor: 0.684

Review 6.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

7.  Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center.

Authors:  J H Leitão; S A Sousa; M V Cunha; M J Salgado; J Melo-Cristino; M C Barreto; I Sá-Correia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-04       Impact factor: 3.267

8.  Burkholderia cenocepacia, B. multivorans, B. ambifaria and B. vietnamiensis isolates from cystic fibrosis patients have different profiles of exoenzyme production.

Authors:  Ana Paula D'Allicourt Carvalho; Grasiella Maria Carvalho Ventura; Carolina Borges Pereira; Robson Souza Leão; Tânia Wrobel Folescu; Laurinda Higa; Lucia Martins Teixeira; Maria Cristina Maciel Plotkowski; Vânia Lucia Carreira Merquior; Rodolpho Mattos Albano; Elizabeth Andrade Marques
Journal:  APMIS       Date:  2007-04       Impact factor: 3.205

9.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

10.  Polyphasic characterisation of Burkholderia cepaciacomplex species isolated from children with cystic fibrosis.

Authors:  Fernando José Vicenzi; Marcelo Pillonetto; Helena Aguilar Peres Homem de Mello de Souza; Jussara Kasuko Palmeiro; Carlos Antônio Riedi; Nelson Augusto Rosario-Filho; Libera Maria Dalla-Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-01       Impact factor: 2.743

View more
  1 in total

1.  Case Report: Community-Acquired Burkholderia cepacia Pneumonia of a Patient with Pulmonary Tuberculosis.

Authors:  Qiang Li; Li-Ping Ma
Journal:  Am J Trop Med Hyg       Date:  2022-06-13       Impact factor: 3.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.